Clinical Trial

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Study acronym: PAM-VET
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-05-19; most recent amendment 2025-09-29.
Status change: Not Yet Recruiting → Recruiting 2025-09-29
Trial Details
NCT Number NCT06989957
Lead Sponsor Johns Hopkins University
Collaborators: Gracias Family Foundation
Conditions Posttraumatic Stress Disorder
Enrollment 40 participants
Start Date 2025-09-17
Primary Completion 2028-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-01